On these pages you can check out the latest breast cancer news from BCAC and our member groups. We also provide up-to-date information and links to current breast cancer research and clinical trials. Read latest stories below, or use the filters or the pager below for other stories. Use the form to the right of this to subscribe to our e-News.
New research has found that random and unpredictable DNA copying “mistakes” are responsible for nearly two-thirds of the mutations that cause cancer.
This means “environmental” influences, such as nutrition and exercise, play less of a role in many cancer cases than previously thought.
Eating foods rich in isoflavones, which are found in soy products, could help to reduce the death rate in women with certain types of breast cancer.
A new study, published in the journal Cancer, found that isoflavones are associated with lower death rates in women with hormone-receptor-negative breast cancer and those who are not receiving endocrine therapy.
New results from a major clinical trial testing the breakthrough breast cancer drug, Perjeta, show that it helped women with early HER-2 Positive breast cancer live longer.
Headline results from the Phase III APHINITY trial have just been released by the pharmaceutical company Roche.
Breast cancer patients with dense breasts are twice as likely to develop cancer in the other breast, according to new research.
The study, published in the journal Cancer, is one of the first to describe the association between breast density and the risk of cancer in the non-cancerous or contralateral breast.
New Zealand researchers will soon use cutting-edge genetic technology to help control resistance to the latest drug for treating HER2-positive breast cancer that has spread to other parts of the body.
New research has found that hormones produced by fat cells in obese women can promote the growth of breast cancer cells, while exercise may help to stop the cancer from growing.
The study, published in the Journal of Applied Physiology, highlights the crucial role of fat cells and the hormones they produce in the growth of breast cancer.
Taking hormone drugs for more than ten years could help to dramatically reduce the risk of breast cancer recurrence, according to a landmark study.
A randomised clinical trial involving nearly 2,000 women found that cancer recurrence dropped by a third in those who took hormone drugs for ten years rather than the standard five.
Researchers hope that three new breakthrough drugs designed to target triple negative breast cancer could potentially transform therapy for those with the hard-to-treat disease.
There are currently no targeted therapies for those with triple negative breast cancer leaving medical care reliant on traditional treatments such as chemotherapy and radiotherapy.
Scientists say they now have a near-perfect picture of the genetic events that cause breast cancer.
The study, published in Nature, has been described as a "milestone" moment that could help unlock new ways of treating and preventing the disease.
The largest study of its kind unpicked practically all the errors that cause healthy breast tissue to go rogue.
A new study shows that post-menopausal women who stayed on a low fat diet for around eight years had improved breast cancer survival rates compared with women who were not on a low fat diet.
The Los Angeles Biomedical Research Institute study was presented at the American Association for Cancer Research Annual Meeting.